CHICAGO – Phase III Impower131 findings with Tecentriq (atezolizumab, Roche Holding AG) when combined with chemotherapy in squamous-cell lung cancer, along with separate discoveries related to a would-be new blood test for early stage lung cancer emerged at the American Society of Clinical Oncology (ASCO) meeting.